Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial

BACKGROUND: Needle-free delivery improves the immunogenicity of DNA vaccines but is also associated with more local reactogenicity. Here we report the first comparison of Biojector and needle administration of a candidate rAd5 HIV vaccine. METHODS: Thirty-one adults, 18–55 years, 20 naive and 11 pri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sarwar, Uzma N., Novik, Laura, Enama, Mary E., Plummer, Sarah A., Koup, Richard A., Nason, Martha C., Bailer, Robert T., McDermott, Adrian B., Roederer, Mario, Mascola, John R., Ledgerwood, Julie E., Graham, Barney S.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2014
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4179264/
https://ncbi.nlm.nih.gov/pubmed/25264782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0106240
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars